Luke Henry | VP Operations & Corporate Development
Quell Therapeutics

Luke Henry, VP Operations & Corporate Development, Quell Therapeutics

Luke serves as Vice President Operations & Corporate Development where is responsible for portfolio strategy, corporate/business development, business operations, and legal functions. He joined Quell from Neon Therapeutics where he served as Senior Director of Business Development & Strategy working across business development, strategic planning, and driving the execution of Neon?s T cell therapy strategy and programs, as well as supporting the company?s IPO on the Nasdaq. Prior to joining Neon, Luke was a principal with Boston Consulting Group where he advised global pharma and biotech clients on corporate strategy, M&A, R&D portfolio, drug development focused on Immuno-Oncology assets. Luke holds an MSci in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Molecular and Cellular Oncology from the Institute of Cancer Research, University of London.


Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 17:00

Quell Therapeutics Case Study - Building and funding the journey to develop an engineered Treg cell therapy platform

last published: 10/May/21 08:45 GMT

back to speakers